Literature DB >> 24187471

Angiotensin-II inhibitor (olmesartan)-induced collagenous sprue with resolution following discontinuation of drug.

Jennifer A Nielsen1, Anita Steephen, Matthew Lewin.   

Abstract

Collagenous sprue (CS) is a pattern of small-bowel injury characterized histologically by marked villous blunting, intraepithelial lymphocytes, and thickened sub-epithelial collagen table. Clinically, patients present with diarrhea, abdominal pain, malabsorption, and weight loss. Gluten intolerance is the most common cause of villous blunting in the duodenum; however, in a recent case series by the Mayo Clinic, it has been reported that olmesartan can have a similar effect. In this case report, a 62-year-old female with a history of hypothyroidism and hypertension managed for several years with olmesartan presented with abdominal pain, weight loss, and nausea. Despite compliance to a gluten-free diet, the patient's symptoms worsened, losing 20 pounds in 3 wk. Endoscopy showed thickening, scalloping, and mosaiform changes of the duodenal mucosa. The biopsy showed CS characterized by complete villous atrophy, lymphocytosis, and thickened sub-epithelial collagen table. After 2 mo cessation of olmesartan, the patient's symptoms improved, and follow-up endoscopy was normal with complete villous regeneration. These findings suggest that olmesartan was a contributing factor in the etiology of this patient's CS. Clinicians should be aware of the possibility of drug-induced CS and potential reversibility after discontinuation of medication.

Entities:  

Keywords:  Celiac disease; Collagenous sprue; Duodenum; Olmesartan; Patient-drug interaction

Mesh:

Substances:

Year:  2013        PMID: 24187471      PMCID: PMC3812495          DOI: 10.3748/wjg.v19.i40.6928

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  4 in total

1.  Severe spruelike enteropathy associated with olmesartan.

Authors:  Alberto Rubio-Tapia; Margot L Herman; Jonas F Ludvigsson; Darlene G Kelly; Thomas F Mangan; Tsung-Teh Wu; Joseph A Murray
Journal:  Mayo Clin Proc       Date:  2012-06-22       Impact factor: 7.616

2.  Update on collagenous sprue.

Authors:  Hugh James Freeman
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

3.  The histologic spectrum and clinical outcome of refractory and unclassified sprue.

Authors:  M E Robert; M E Ament; W M Weinstein
Journal:  Am J Surg Pathol       Date:  2000-05       Impact factor: 6.394

4.  Non-gluten sensitivity-related small bowel villous flattening with increased intraepithelial lymphocytes: not all that flattens is celiac sprue.

Authors:  Neal S Goldstein
Journal:  Am J Clin Pathol       Date:  2004-04       Impact factor: 2.493

  4 in total
  13 in total

1.  Immunopathogenesis of olmesartan-associated enteropathy.

Authors:  E V Marietta; A M Nadeau; A K Cartee; I Singh; A Rishi; R S Choung; T-T Wu; A Rubio-Tapia; J A Murray
Journal:  Aliment Pharmacol Ther       Date:  2015-10-01       Impact factor: 8.171

2.  Olmesartan, other antihypertensives, and chronic diarrhea among patients undergoing endoscopic procedures: a case-control study.

Authors:  Ruby Greywoode; Eric D Braunstein; Carolina Arguelles-Grande; Peter H R Green; Benjamin Lebwohl
Journal:  Mayo Clin Proc       Date:  2014-07-11       Impact factor: 7.616

3.  Telmisartan-induced sprue-like enteropathy: a case report.

Authors:  Natalia Alzueta; Amaya Echeverría; Lorea Sanz; Carmen Fontela; Teresa Acín; Lidia Montenegro; Javier Garjón
Journal:  Eur J Hosp Pharm       Date:  2018-09-25

4.  Olmesartan-related sprue-like enteropathy.

Authors:  Naresh Bhat; N K Anupama; Amit Yelsangikar; Kayal Vizhi
Journal:  Indian J Gastroenterol       Date:  2014-10-12

5.  A Case of Severe Sprue-Like Enteropathy Associated With Valsartan.

Authors:  Margot L Herman; Alberto Rubio-Tapia; Tsung-Teh Wu; Joseph A Murray
Journal:  ACG Case Rep J       Date:  2015-01-16

6.  The first cases of collagenous sprue successfully treated with thioguanine.

Authors:  Tom van Gils; Tine van de Donk; Gerd Bouma; Foke van Delft; E Andra Neefjes-Borst; Chris J J Mulder
Journal:  BMJ Open Gastroenterol       Date:  2016-06-27

7.  Small bowel enteropathy associated with olmesartan medoxomil treatment.

Authors:  Michail Galanopoulos; Lazaros Varytimiadis; Athanasios Tsigaridas; Pantelis S Karatzas; Emmanuel Archavlis; Nikos Viazis; Christina Vourlakou; Gerassimos J Mantzaris
Journal:  Ann Gastroenterol       Date:  2016-06-03

8.  A Case of Moderate Sprue-Like Enteropathy Associated With Telmisartan.

Authors:  Aurelio Negro; Loredana De Marco; Valentina Cesario; Rosaria Santi; Maria Chiara Boni; Magda Zanelli
Journal:  J Clin Med Res       Date:  2017-11-06

9.  European guidelines on microscopic colitis: United European Gastroenterology and European Microscopic Colitis Group statements and recommendations.

Authors:  Stephan Miehlke; Danila Guagnozzi; Yamile Zabana; Gian E Tontini; Anne-Marie Kanstrup Fiehn; Signe Wildt; Johan Bohr; Ole Bonderup; Gerd Bouma; Mauro D'Amato; Peter J Heiberg Engel; Fernando Fernandez-Banares; Gilles Macaigne; Henrik Hjortswang; Elisabeth Hultgren-Hörnquist; Anastasios Koulaouzidis; Jouzas Kupcinskas; Stefania Landolfi; Giovanni Latella; Alfredo Lucendo; Ivan Lyutakov; Ahmed Madisch; Fernando Magro; Wojciech Marlicz; Emese Mihaly; Lars K Munck; Ann-Elisabeth Ostvik; Árpád V Patai; Plamen Penchev; Karolina Skonieczna-Żydecka; Bas Verhaegh; Andreas Münch
Journal:  United European Gastroenterol J       Date:  2021-02-22       Impact factor: 4.623

10.  Sprue-Like Enteropathy Associated With Olmesartan: A New Kid on the Enteropathy Block.

Authors:  Isabel A Hujoel; Alberto Rubio-Tapia
Journal:  GE Port J Gastroenterol       Date:  2016-03-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.